BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16117812)

  • 1. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.
    Xing M
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):263-6. PubMed ID: 16117812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients.
    Cañadas-Garre M; Becerra-Massare P; López de la Torre-Casares M; Villar-del Moral J; Céspedes-Mas S; Vílchez-Joya R; Muros-de Fuentes T; García-Calvente C; Piédrola-Maroto G; López-Nevot MA; Montes-Ramírez R; Llamas-Elvira JM
    Ann Surg; 2012 May; 255(5):986-92. PubMed ID: 22504197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
    Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
    Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
    Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
    Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
    Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
    J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families.
    Suh I; Filetti S; Vriens MR; Guerrero MA; Tumino S; Wong M; Shen WT; Kebebew E; Duh QY; Clark OH
    Surgery; 2009 Dec; 146(6):1073-80. PubMed ID: 19958934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status.
    Cradic KW; Milosevic D; Rosenberg AM; Erickson LA; McIver B; Grebe SK
    J Clin Endocrinol Metab; 2009 Dec; 94(12):5001-9. PubMed ID: 19850689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
    Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
    J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma.
    Kim HS; Kim JO; Lee DH; Lee HC; Kim HJ; Kim JH; Jang YS; Lee JM; Kim SY; Kim YS
    Oncol Rep; 2011 Jun; 25(6):1639-44. PubMed ID: 21431280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
    Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes.
    Vasko V; Hu S; Wu G; Xing JC; Larin A; Savchenko V; Trink B; Xing M
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5265-9. PubMed ID: 15998781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma.
    Trovisco V; Couto JP; Cameselle-Teijeiro J; de Castro IV; Fonseca E; Soares P; Sobrinho-Simões M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):683-5. PubMed ID: 18363883
    [No Abstract]   [Full Text] [Related]  

  • 13. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis.
    Oler G; Ebina KN; Michaluart P; Kimura ET; Cerutti J
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):509-11. PubMed ID: 15807885
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer.
    Moses W; Weng J; Kebebew E
    Thyroid; 2011 Apr; 21(4):367-71. PubMed ID: 21190444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway.
    Frich L; Glattre E; Akslen LA
    Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):113-7. PubMed ID: 11219767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T1799A BRAF mutations in conjunctival melanocytic lesions.
    Goldenberg-Cohen N; Cohen Y; Rosenbaum E; Herscovici Z; Chowers I; Weinberger D; Pe'er J; Sidransky D
    Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3027-30. PubMed ID: 16123397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
    Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-Scarrà G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G;
    J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The T1799A BRAF mutation is present in iris melanoma.
    Henriquez F; Janssen C; Kemp EG; Roberts F
    Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):4897-900. PubMed ID: 17962436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population.
    de Randamie R; Martos-Moreno GÁ; Lumbreras C; Chueca M; Donnay S; Luque M; Regojo RM; Mendiola M; Hardisson D; Argente J; Moreno JC
    Horm Res Paediatr; 2018; 89(6):397-407. PubMed ID: 29895015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic features of familial nonmedullary thyroid carcinoma.
    Fan YF; Zhang B; Yang X; Shang ZH; Liu HF; Xie Y; Liu YW; Gao WS; Wu Q; Li XY
    Chin Med J (Engl); 2015 Apr; 128(8):1037-41. PubMed ID: 25881596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.